| Karen Marie Orlosky, AA | |
|
9850 Arapahoe Rd, Lafayette, CO 80026-9306 | |
| (330) 242-1524 | |
| Not Available |
| Full Name | Karen Marie Orlosky |
|---|---|
| Gender | Female |
| Speciality | Massage Therapist |
| Location | 9850 Arapahoe Rd, Lafayette, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093747834 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 67000049 (Ohio) | Secondary |
| 225700000X | Massage Therapist | 13085 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karen Marie Orlosky, AA 9850 Arapahoe Rd, Lafayette, CO 80026-9306 Ph: (330) 242-1524 | Karen Marie Orlosky, AA 9850 Arapahoe Rd, Lafayette, CO 80026-9306 Ph: (330) 242-1524 |
News Archive
Although life expectancy has improved and infant mortality has fallen in Israel, the country's health system still faces significant challenges, report researchers.
The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all. Researchers reporting online on August 13th in the journal Cell, a Cell Press publication, have discovered the first compound that targets those cancer stem cells directly.
Commenting on the release today of the DHSSPS's NHS waiting list figures, BMA(NI) Chairman, Dr Brian Patterson, said that the reduction in numbers of people waiting for inpatient treatment, albeit small, was to be welcomed and paid tribute to the doctors, nurses and other healthcare staff who have worked hard to achieve this.
Two research projects at the University of Bristol have been awarded over £600,000 in total, to help provide greater understanding of epilepsy, the most common serious primary brain disorder in the UK
Boston Scientific Corporation today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire Asthmatx, Inc., a privately held company in Sunnyvale, California. Asthmatx designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma in the 6 to 8 million patients 18 years and older worldwide whose asthma is not well controlled with drugs (inhaled medications).
› Verified 8 days ago